Julia Rotow, MD

Articles

Emerging Strategies for ALK+ NSCLC

December 5th 2025

Panelists discuss novel research directions aimed at overcoming resistance and extending survival in ALK-positive lung cancer.

Resistance Mechanisms and Molecular Testing in ALK Inhibitor–Treated NSCLC

December 5th 2025

Panelists discuss mechanisms of acquired resistance to ALK inhibition and how molecular testing guides sequencing strategies.

Selecting Candidates for HER2 TKIs

December 4th 2025

Explore a case study on HER2 mutant lung cancer treatment, highlighting challenges and responses to chemotherapy and immunotherapy.

Zongertinib After ADC Therapy: Efficacy, Safety, and Clinical Context

December 4th 2025

Explore a case study on HER2 mutant lung cancer treatment, highlighting challenges, responses, and the importance of monitoring for ILD.

Real-World Data in ALK+ NSCLC

November 26th 2025

Panelists discuss how real-world data complement clinical trials in understanding outcomes for ALK-positive lung cancer.

Using Long-Term Data to Guide ALK+ NSCLC Treatment

November 26th 2025

Panelists discuss how mature survival data inform treatment sequencing and maintenance strategies in ALK-positive lung cancer.

Case 1: Managing HER2-Mutant NSCLC and ILD

November 25th 2025

Explore a case study on HER2 mutant lung cancer treatment, highlighting challenges and responses to therapy in a patient with metastatic disease.

Understanding HER2 Alterations in Non–Small Cell Lung Cancer

November 25th 2025

Explore innovative strategies for testing and treating HER2 alterations in non-small cell lung cancer through real-world case studies and expert insights.

Investigational Therapies and Ongoing Trials in ROS1+ NSCLC

November 12th 2025

Panelists discuss ongoing research and investigational strategies aimed at overcoming resistance in ROS1-driven lung cancer.

Use of ROS1-Targeting Agents in Clinical Practice

November 12th 2025

Panelists discuss translating clinical trial evidence on ROS1-targeted therapy into real-world patient management.

ALK Alterations and Treatment Options for ALK+ NSCLC

November 5th 2025

Panelists discuss the role of ALK rearrangements in lung cancer and the development of successive generations of targeted inhibitors.

Long-Term Data in ALK+ NSCLC

November 5th 2025

Panelists discuss long-term data demonstrating the durability of response and intracranial protection achieved with modern ALK-targeted therapies.

Spotlight on ROS1-Targeted Therapies in Advanced NSCLC

November 5th 2025

Panelists discuss the molecular and clinical characteristics of ROS1-driven lung cancer and the role of precise molecular testing in guiding targeted therapy.

Treatment Options for ROS1+ Advanced NSCLC

November 5th 2025

Panelists discuss first-line treatment strategies for ROS1-positive lung cancer and the factors influencing therapy selection and sequencing.

Updated overall survival analysis from the phase 2 PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC)

October 30th 2025

An expert discusses updated overall survival results from the phase 2 PHAROS study evaluating encorafenib plus binimetinib in patients with BRAF V600E–mutant metastatic non–small cell lung cancer (mNSCLC).

Unmet Needs to Address in Advanced NSCLC

October 16th 2025

Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss unmet needs in advanced NSCLC.

Novel Biomarkers to Watch in Advanced NSCLC

October 16th 2025

Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss novel biomarkers under investigation in advanced NSCLC.

Exploring Sigvotatug Vedotin–Based Combinations in Advanced NSCLC

October 7th 2025

Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss the investigation of sigvotatug vedotin plus pembrolizumab in NSCLC.

Evaluation of Sigvotatug Vedotin Monotherapy in Previously Treated, Nonsquamous NSCLC

October 7th 2025

Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss the investigation of sigvotatug vedotin in nonsquamous NSCLC.

Treatment Approaches and Unmet Needs in Second-Line Advanced NSCLC

September 22nd 2025

Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss unmet needs in second-line non–small cell lung cancer.